| A Journey from Blood Cells to Genes and Back |
|
Annual Review of Genomics and Human Genetics |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| A novel approach to defining progression in MDS and precursor myeloid conditions in The MDS Natural History Study |
|
Blood Advances |
Myelodysplastic Syndromes (MDS) |
| A novel approach to defining progression in MDS and precursor myeloid conditions in the MDS Natural History Study |
|
Blood Advances |
Myelodysplastic Syndromes (MDS) |
| A Personalized Prediction Model for Outcomes after Allogeneic Hematopoietic Cell Transplant in Patients with Myelodysplastic Syndromes |
|
Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation |
Myelodysplastic Syndromes (MDS) |
| A Personalized Prediction Model for Outcomes after Allogeneic Hematopoietic Cell Transplant in Patients with Myelodysplastic Syndromes |
|
Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation |
Myelodysplastic Syndromes (MDS) |
| A phase 2 trial of the oral smoothened inhibitor glasdegib in refractory myelodysplastic syndromes (MDS) |
|
Leukemia Research |
Myelodysplastic Syndromes (MDS) |
| A phase 3 randomized study of 5-azacitidine maintenance vs observation after transplant in high-risk AML and MDS patients |
|
Blood Advances |
Myelodysplastic Syndromes (MDS) |
| A Phase II Study to Determine the Safety and Efficacy of the Oral Inhibitor of Indoleamine 2,3-Dioxygenase (IDO) Enzyme INCB024360 in Patients with Myelodysplastic Syndromes |
|
Clin Lymphoma Myeloma Leuk |
Myelodysplastic Syndromes (MDS) |
| A stimulating advance in erythropoiesis for patients with myelodysplastic syndromes |
|
Lancet Haematology |
Myelodysplastic Syndromes (MDS) |
| A stimulating advance in erythropoiesis for patients with myelodysplastic syndromes |
|
Lancet Haematology |
Myelodysplastic Syndromes (MDS) |
